Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.24.1.1.u2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 101,080 $ 65,222
Accounts receivable, net 0 740
Grant receivable 21,042 76,266
Prepaid expenses 29,471 44,891
Total current assets 151,593 187,119
Property and equipment, net 44,524 50,943
Right to use assets 70,658 97,278
Other assets:    
Patents, net 8,733 9,027
Deposits, long term 41,936 44,520
Total other assets 50,669 53,547
Total assets 317,444 388,887
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,787,403 and $1,683,453, respectively 4,976,775 4,649,179
Lease liability, short term 104,062 122,732
Derivative liability 80,190 53,460
Notes payable, net of debt discount of $378,530 and $354,730, respectively 802,950 606,750
Notes payable, related parties, net of debt discount of $48,110 and $77,295, respectively 1,204,153 999,088
Total current liabilities 7,168,130 6,431,209
Long term liabilities:    
Economic Injury Disaster loan, long term 72,112 72,466
Royalty obligation, net of discount of $4,780,800 and $4,899,354, related parties 3,941,300 3,822,746
Lease liability, long term 0 10,945
Deferred revenue, long term 4,045 4,045
Total liabilities 11,185,587 10,341,411
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 8,897,104 and 8,674,029 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 8,897 8,674
Common stock subscribed 100,009 100,009
Additional paid in capital 68,470,650 68,149,029
Accumulated deficit (79,339,794) (78,103,018)
Total deficit attributable to BioCorRx Inc. (10,738,622) (9,823,690)
Non-controlling interest (129,521) (128,834)
Total deficit (10,868,143) (9,952,524)
Total liabilities and deficit 317,444 388,887
Series A Convertible Preferred Stock [Member]    
Deficit:    
Preferred stock value 16,000 16,000
Series B Convertible Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616